UP-TITRATION TO HIGH-DOSE 13.3 MG/24 H RIVASTIGMINE TRANSDERMAL PATCH MAY PROVIDE GREATER BENEFIT TO ALZHEIMER'S DISEASE PATIENTS COMPARED TO CONCOMITANT USE OF 9.5 MG/24 H PATCH AND MEMANTINE: RESULTS FROM THE OPTIMA STUDY

Journal article

Peer reviewed

José L. Molinuevo, Jeffrey Cummings, Lutz Frolich, James E. Galvin, Tillmann Krahnke and Christine Strohmaier

Alzheimer's & dementia, Vol.10(4), pp.P856-P857

2014-07

Metrics

4 Record Views

Title: UP-TITRATION TO HIGH-DOSE 13.3 MG/24 H RIVASTIGMINE TRANSDERMAL PATCH MAY PROVIDE GREATER BENEFIT TO ALZHEIMER'S DISEASE PATIENTS COMPARED TO CONCOMITANT USE OF 9.5 MG/24 H PATCH AND MEMANTINE: RESULTS FROM THE OPTIMA STUDY
Creators: José L. Molinuevo - Pasqual Maragall Foundation
Jeffrey Cummings - Lou Ruvo Brain Institute
Lutz Frolich - Central Institute of Mental Health
James E. Galvin - NYU Langone Health
Tillmann Krahnke - Novartis
Christine Strohmaier - Novartis
Publication Details: Alzheimer's & dementia, Vol.10(4), pp.P856-P857
Publisher: Elsevier Inc
Academic Unit: Miller School of Medicine; UMMG Department of Neurology
Language: English
Resource Type: Journal article
Record Identifier: 991031739726402976